Dr. Hubert Heinrichs, CEO & CMO der Antisense Pharma GmbH

Hubert Heinrichs is acting Chief Executive Officer of Antisense Pharma since 2011 and Chief Medical Officer since 2006. He has over 20 years of pharmaceutical industry experience. Prior to joining Antisense Pharma, he was responsible at Aventis Behring for the worldwide coordination of all clinical studies from Phase I to IV and also for the clinical part of dossiers of five approved innovative medications in Europe and the USA. He received his medical degree from the Eberhard Karls University in Tübingen, Germany. He is specialized in immunology with 3 years of post-doctoral research fellowship at the Department of Human Genetics, University of Minnesota, USA, and held appointments at the Max-Planck Institute for Immunology in Tübingen, Germany, as well as the Institute for Immunology in Basel, Switzerland. He earned his M.B.A. at the Aston Business School in Birmingham, UK.